Predicting outcomes of behavioral therapy for anxiety and depression
An Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome in Anxiety and Depression (AAC-BeT)
This study is testing different types of therapy for people with both anxiety and depression to see which one helps them feel better in the long run.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 220 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Laureate Institute for Brain Research, Inc. Academic / other |
| Locations | 1 site (Tulsa, Oklahoma) |
| Trial ID | NCT04426461 on ClinicalTrials.gov |
What this trial studies
This study aims to improve treatment outcomes for individuals suffering from both anxiety and depression by utilizing a computational framework that assesses approach-avoidance decision-making. Participants will be randomized to receive one of three interventions: Behavioral Activation, Exposure-based therapy, or Supportive therapy. The study focuses on understanding which therapeutic strategies are most effective for patients with comorbid symptoms, as current treatments often yield limited long-term benefits. By analyzing responses to potential rewards and threats, the research seeks to inform better treatment decisions for these common mental health conditions.
Who should consider this trial
Good fit: Ideal candidates include individuals experiencing significant anxiety and depressive symptoms, as indicated by specific scoring thresholds on validated scales.
Not a fit: Patients with severe mental health conditions, such as bipolar disorder or PTSD, or those with significant physical health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatment strategies for patients with anxiety and depression.
How similar studies have performed: While the approach of integrating decision-making paradigms into therapy is innovative, similar studies have shown promise in improving treatment outcomes for anxiety and depression.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * score \>55 on both the PROMIS Anxiety and PROMIS Depression scales * score \>5 on any one item of the SDS * able to provide informed consent * report of anxiety and depressive symptoms as areas of clinical concern * sufficient English proficiency to complete procedures. Exclusion Criteria: * significant or unstable physical or mental health conditions (e.g., immediate suicidal intent) requiring medical attention * history of bipolar, psychotic, cognitive, obsessive compulsive disorder, posttraumatic stress disorder (PTSD) * history of moderate to severe substance use disorder over the past year * diagnosis of neurologic disorders * MRI contra-indications (e.g., metal in body) * uncorrected vision/hearing problems * current, regular benzodiazepine use
Where this trial is running
Tulsa, Oklahoma
- Laureate Institute for Brain Research — Tulsa, Oklahoma, United States (Recruiting)
Study contacts
- Principal investigator: Robin L Aupperle, PhD — Laureate Institute for Brain Research
- Study coordinator: Mallory Cannon, M.S.
- Email: neurocatt@laureateinstitute.org
- Phone: 918-581-4885
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.